Two new clinical studies challenge the optimism around psilocybin as a treatment for depression. A German trial found psilocybin no significantly better than an active placebo, while a UCSF meta-analysis of open-label studies found psychedelics no more effective than traditional antidepressants. A key methodological problem is
Sort: